Table 4.
Enriched canonical pathways in endometrial mRNA from HF and LF heifers
| Pathways | Genes | % DEG | P -value |
|---|---|---|---|
| Canonical signalling | |||
| Regulation of Actin-based Motility by Rho | MYLK, ACTB, ACTA2, RHOU, ACTC1, FNBP | 6.5 | 0.0007 |
| ILK Signalling | TGFB1I1, FLNC, ACTN2, ACTB, ACTA2, FERMT2, RHOU, ACTC1, FNBP1 | 4.3 | 0.0017 |
| Caveolar-mediated Endocytosis Signalling | FLNC, ACTB, ACTA2, ACTC1, COPB2 | 6.0 | 0.0024 |
| Polyamine Regulation in Colon Cancer | PSMD11, PSMB10, PSMD2, ODC1 | 7.0 | 0.0041 |
| Cellular Effects of Sildenafil | MYLK, ADCY2, ACTB, ACTA2, ADCY3, ACTC1 | 3.9 | 0.0068 |
| RhoA Signalling | MYLK, ACTB, ACTA2, ARHGEF11, ACTC1 | 4.5 | 0.0126 |
| Mechanisms of Viral Exit from Host Cells | ACTB, ACTA2, ACTC1 | 6.8 | 0.0135 |
| TR/RXR Activation | UCP3 , RAB3B , FASN, RCAN2 | 4.1 | 0.0245 |
| Virus Entry via Endocytic Pathways | FLNC, ACTB, ACTA2, ACTC1 | 4.2 | 0.0245 |
| Semaphorin Signalling in Neurons | DPYSL3, RHOU, FNBP1 | 5.8 | 0.0288 |
| HMGB1 Signalling | HMGB1 (includes EG:3146), RBBP7, RHOU, FNBP1 | 4.1 | 0.0302 |
| Thrombin Signalling | MYLK, ADCY2, ADCY3, RHOU, ARHGEF11, FNBP1 | 2.9 | 0.0331 |
| Integrin Signalling | MYLK, ACTB, ACTA2, RHOU, ACTC1, FNBP1 | 3.0 | 0.0331 |
| Sphingosine-1-phosphate Signalling | ADCY2, ADCY3, RHOU, FNBP1 | 3.6 | 0.0407 |
| Germ Cell-Sertoli Cell Junction Signalling | ACTB, ACTA2, RHOU, ACTC1, FNBP1 | 3.2 | 0.0417 |
| CXCR4 Signalling | ADCY2, ADCY3, RHOU, ARHGEF11, FNBP1 | 3.0 | 0.0447 |
| Canonical metabolic | |||
| Purine Metabolism | NSF , ADCY2, ENPP1, IMPDH2, DCK , ATP13A5, ADCY3, PDE6C , PAICS, POLR2H, ACTC1 | 2.5 | 0.0019 |
| Glycan Biosynthesis | GALNT2, GYLTL1B , GALNT6 | 6.3 | 0.0077 |
| Fatty Acid Biosynthesis | FASN, PCCB | 3.9 | 0.0098 |
| Sulphur Metabolism | SULT1A1, SUOX | 3.3 | 0.0316 |
| Pantothenate and CoA Biosynthesis | ENPP1, DPYSL3 | 3.1 | 0.0347 |
| Pyrimidine Metabolism | ENPP1, DCK , DPYSL3, POLR2H, CMPK1 | 2.2 | 0.0457 |
Genes marked in bold are up-regulated.